Dengue infection in congenital bleeding disorders registry
Part of Infections clinical trials.
This study creates a registry to track how dengue infection affects people with congenital bleeding disorders, such as hemophilia. It aims to learn more about managing dengue in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 1 day old (any age can join)
- You have a congenital bleeding disorder such as hemophilia or von Willebrand disease
- You also have dengue infection confirmed by a doctor (based on fever, blood tests, or signs of bleeding)
- You are willing to have your medical information recorded for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with dengue need to be hospitalized or get a blood transfusion. It aims to make care safer and help doctors know who needs closer monitoring.
This study tests if a dengue vaccine (TDV) can reduce hospital stays for dengue. It follows children and teens in areas where dengue vaccination is planned.
This study follows patients hospitalised with dengue to better understand the disease and improve future research. If you are in the hospital with confirmed dengue, you may be eligible to join.
This trial tests new strategies to treat dengue, ranging from mild to severe cases. It may help people with different stages of dengue find better care and support.
This study collects blood samples from people with suspected or confirmed dengue to help improve testing. Participation may help researchers understand the disease better and could lead to better diagnostics.
This trial tests new treatments for people hospitalized with moderate to severe dengue, a mosquito-borne illness. It aims to find better ways to reduce symptoms and prevent serious complications.
Hear when a new Dengue Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.